Evidence map›Paper›PMID 41750253›Full record

ArticleBiomolecules2026

Selective Complement Inhibition in Anti-p200 Pemphigoid: Immune Infiltrate Profiles and Therapeutic Implications Compared to Bullous Pemphigoid.

Shirin Emtenani, Tina Rastegar Lari, Charlotte Kiehne, Nina van Beek, Maike M Holtsche, Enno Schmidt

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shirin EmtenaniLübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany.ORCID 0000-0002-7965-8045
Tina Rastegar LariLübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany.
Charlotte KiehneDepartment of Dermatology, Schleswig-Holstein University Hospital, Campus Lübeck, 23562 Lübeck, Germany.
Nina van BeekLübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany.ORCID 0000-0002-3265-0011
Maike M HoltscheLübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany.
Enno SchmidtLübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany.

Funding

CRC 1526 Pathomechanisms of Antibody-338 mediated Autoimmunity A01CRU 303 Pemphigoid DiseasesGerman Research Foundation (DFG) DFG EM 362/1-1German Research Foundation (DFG) through the Schles-336 wig-Holstein Excellence Cluster Precision Medicine in Chronic Inflammation DFG EXC 2167/1University of Lübeck H02-2024University of Lübeck J13-2022
6 · The paper itself

Abstract

Anti-p200 pemphigoid is an autoimmune blistering disease (AIBD) caused by autoantibodies against laminin β4 and/or γ1, and clinically resembles bullous pemphigoid (BP) as well as the inflammatory variant of epidermolysis bullosa acquisita (EBA). All three diseases show IgG and/or C3 deposition along the cutaneous basement membrane zone (BMZ). Although complement activation is central to BP and EBA pathogenesis, its role in anti-p200 pemphigoid remains unclear. To investigate this, we analyzed inflammatory infiltrates in lesional and perilesional skin from anti-p200 pemphigoid patients (

Indexed as

AutoantibodiesComplement Inactivating AgentsLamininPemphigoid, BullousAgedAged, 80 and overComplement ActivationComplement C3Complement C3cEosinophilsEpidermolysis Bullosa AcquisitaFemaleHumansMaleMiddle AgedNeutrophilsAutoantibodiesC5AR1 protein, humanComplement C3Complement C3cComplement Inactivating AgentscompstatinLamininlaminin gamma 1Peptides, CyclicReceptor, Anaphylatoxin C5aanti-p200 pemphigoidautoimmune blistering diseasebullous pemphigoidcomplement fixationcomplement inhibitioneosinophilneutrophil

Identifiers

PMID41750253
PMCPMC12938136

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.